Pain Management – Narcotic Analgesics – Short-Acting

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS – Maximum Days' Supply Allowed	PR – Enrollment in a Physician- Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana 1-855-242-0802 AmeriHealth Caritas Louisiana 1-800-684-5502 Fee-for-Service (FFS) Louisiana Legacy Medicaid 1-866-730-4357 Healthy Blue 1-844-521-6942

Louisiana Healthcare Connections **1-888-929-3790** UnitedHealthcare **1-800-310-6826**

Pain Management - Narcotic Analgesics - Short-Acting

POS Edits

- **AL** Some agents are limited to use in recipients who are within agent-specific age ranges.
 - Codeine single-ingredient products are limited to use in recipients who are at least 18 years of age. Codeine combination products are limited to use in recipients who are at least 12 years of age.
 - Tramadol (tablets/solution) and tramadol combination products are limited to use in recipients who are at least 12 years old.*

 *Use of tramadol products for recipients 12 to less than 18 years of age will require authorization following THIS CRITERIA.
- **BY** Bypass diagnosis codes can be found at THIS LINK.
 - With the exception of fentanyl buccal and sublingual agents, pharmacy claims submitted with a diagnosis code for cancer, palliative end-of-life care, second or third degree burns or corrosions, or sickle cell crisis, will bypass the quantity limits.
 - Pharmacy claims for any short-acting narcotic analgesic, when submitted with a diagnosis code for cancer, palliative end-of-life care, second or third degree burns or corrosions, or sickle cell crisis, will bypass the maximum morphine milligram equivalent (MME) limit.
 - Pharmacy claims for any short-acting narcotic analgesic, when submitted with a diagnosis code for cancer or palliative end-of-life care, will bypass the restriction on concurrent use of opioids with benzodiazepines.
- CU Concurrent use of opioid analgesics and benzodiazepines is monitored at the pharmacy POS.
 - Pharmacy claims for an opioid analgesic will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for a benzodiazepine.
- **DD** Pharmacy claims for any opioid (including buprenorphine-containing products) will deny for drug-drug interaction when the recipient has an active prescription (a prescription in which the days' supply has not expired) for naltrexone tablets or naltrexone extended-release injectable suspension (Vivitrol®) and vice versa.

DX

- Pharmacy claims for all Schedule II opioid prescriptions must be submitted with a valid diagnosis code.
- Pharmacy claims for fentanyl buccal and sublingual agents must be submitted with a cancer-related diagnosis code (C00.*-C96.*).
- * Any number or letter or combination of **UP TO FOUR** numbers and letters of an assigned ICD-10-CM diagnosis code
- **MD** Pharmacy claims for some agents are limited to a maximum daily dose.
 - Tapentadol immediate-release formulation is limited to a maximum daily dose of 700mg per day.
 - Tramadol immediate-release tablets and oral solution are limited to a maximum daily dose based on age:
 - o 400mg/day for recipients who are younger than 76 years of age;
 - o 300mg/day for recipients who are older than 75 years of age.
 - Tramadol/acetaminophen is limited to a maximum daily dose of 8 tablets per day.
 - Tramadol/celecoxib is limited to a maximum daily dose of 4 tablets per day.

MME – The cumulative daily morphine milligram equivalent (MME) for all active opioid prescriptions will be limited to a maximum of 90 MME per day. *Requests to override the MME limit should follow* THIS CRITERIA.

Pain Management – Narcotic Analgesics – Short-Acting

POS Edits						
	No Opioid Claim in Previous 90-days		Opioid Claim in Previous 90-days			
	Generic	7-day Quantity Limit	Generic	30-day Quantity Limit		
QL – Quantity limits for short-acting narcotic analgesics are based upon the recipient's recent history of opioid use. Requests to override the Quantity Limit should follow THIS CRITERIA.	Codeine/Acetaminophen	28 units	Codeine/Acetaminophen	Not Addressed		
	Benzhydrocodone/Acetaminophen	28 units	Benzhydrocodone/Acetaminophen	45 units		
	Fentanyl Buccal/Sublingual	Not Addressed	Fentanyl Buccal/Sublingual	120 units		
	Hydrocodone/Acetaminophen	28 units	Hydrocodone/Acetaminophen	45 units		
	Hydrocodone/Ibuprofen	28 units	Hydrocodone/Ibuprofen	30 units		
	Hydromorphone	28 units	Hydromorphone	45 units		
	Meperidine	28 units	Meperidine	45 units		
	Morphine	28 units	Morphine	45 units		
	Oxycodone	28 units total	Oxycodone	45 units total		
	Oxycodone/Acetaminophen	28 umis iotai	Oxycodone/Acetaminophen			
	Oxymorphone	28 units	Oxymorphone	45 units		
	Tapentadol	28 units	Tapentadol	45 units		
	Tramadol	28 units	Tramadol	45 units		
	Tramadol/Acetaminophen	28 units	Tramadol/Acetaminophen	40 units		
	Tramadol/Celecoxib	28 units	Tramadol/Celecoxib	45 units		

Oral Opioid Liquid Formulation Quantity Limits if No Opioid Claim in Previous 90 days

All oral opioid liquid products have a quantity limit of 6 ounces (180ml) or a 7-day supply (whichever is less) if there is no opioid claim in the previous 90 days.

TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other and with buprenorphine-containing agents.

- These agents are monitored at the pharmacy POS for duplication of therapy with each other (short-acting narcotics with other short-acting narcotics).
- Pharmacy claims for an opioid analgesic for recipients with an active prescription (a prescription in which the days' supply has not expired) for buprenorphine-containing agents will deny.

Pain Management – Narcotic Analgesics – Short-Acting

Revision / Date	Implementation Date	
Created POS Document	February 2020	
Linked the MME and quantity limit criteria / June 2020	June 2020	
Updated age for BH in POS Abbreviations chart / November 2020	January 2021	
Included tramadol solution (Qdolo®) / June 2021	January 2022	
Modified wording for tapentadol and tramadol products / December 2021	April 2022	
Modified age limit for tramadol products / February 2022	July 2022	
Added tramadol/celecoxib and policy clarifications / April 2022	October 2022	